Biocon Biologics

Biocon Biologics gets US FDA approval for biosimilar aflibercept Yesafili, enters US ophthalmology market

by
Biocon Biologics gets US FDA approval for biosimilar aflibercept Yesafili, enters US ophthalmology market

NEW DELHI: Biocon Biologics announced that the US Food and Drug Administration (US FDA) has approved the company’s application for YESAFILI, the company informed the exchange in a filing.“Biocon Biologics’ Obtains US FDA Approval for Biosimilar Aflibercept for Yesafili. Enters US Ophthalmology Market” said the company.After the approval, the company entered the ophthalmology therapeutic area … Read more

Biocon Biologics: Biocon subsidiary grants distribution of biosimilar to Sandoz in Japan

by
Biocon Biologics: Biocon subsidiary grants distribution of biosimilar to Sandoz in Japan

NEW DELHI: Biocon Biologics, a subsidiary of Biocon has signed a distribution agreement with Sandoz, granting the company exclusive rights to promote, sell and distribute `Adalimumab BS for subcutaneous injection [FKB]’* in Japan.Based on this, Viatris has completed marketing and promotion of the product as of December 15, but will continue to provide transition support … Read more

Biocon Biologics: Eris to buy Biocon arm’s brands in Rs 366 crore deal

by
Biocon Biologics: Eris to buy Biocon arm’s brands in Rs 366 crore deal

NEW DELHI: Biocon Biologics (BBL) is divesting its dermatology and nephrology branded formulations business to Eris Lifesciences for Rs 366 crore. The business, which includes its legacy small molecule brands, will be sold as a slump sale, a company statement said. The deal represents an accretive multiple of 4x on revenues and 22x on EBITDA.Post-deal … Read more